Hepalink-backed Aridis Pharmaceuticals has filed to raise up to $34.5m that will support clinical trials for three immunotherapy drug candidates.

The Yahoo Japan and MCN-backed digital media company priced its initial public offering last month before failing to float.

The Johns Hopkins-backed antibody developer floated above its range and has seen its stock almost double in price.

The UC Investment Office-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.

The SR One-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.

The Roche-backed antibody developer floated above its range and has seen its stock almost double in price.

The Tencent-backed livestreaming platform is favouring the US for an initial public offering expected to raise between $600m and $700m.

UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.

The business-focused financial services provider, backed by Sina and Xiaomi, raised $103m in funding last month.

Tencent could buy $250m of shares in the offering for portfolio company Pinduoduo, which will spend the proceeds on growth and R&D.